InvestorsHub Logo
Followers 84
Posts 1928
Boards Moderated 0
Alias Born 03/05/2014

Re: None

Friday, 07/28/2017 1:37:04 PM

Friday, July 28, 2017 1:37:04 PM

Post# of 233151
Take it or leave it. Believe it or not. All IMHO. I hope I covered the disclaimers.

IMO Combo enrollment over enrolled and more than 30 injected. Combo enrollment completion will not be PR'd. Company has their reasons. If we were in their shoes we would agree.

IMO Every effort will be made to PR Combo PE data prior to August 25 meeting. That is in everyone's best interests.

IMO Company expects meeting PE and no safety issues. Key will be how many patients continue on extension study.

IMO Face to face with FDA coming up in September to discuss BLA submission and granting of BTD. Other topic on the table is to open consideration for expanding Combo label to increase patient population. This will dictate how rapidly Pro-140 will move down the approval pathway. Ultimately the likelihood of approval and market value will be more clearly defined.

IMO This sets the stage for attracting a partnership or buy-out and either organic uplist or R/S. The bottom line is CYDY is going to do everything possible to uplist Q4. The OTC is depressing SP and with where Pro-140 is in development it's time to go all in.

Because of all that is in the pipeline and that we as shareholders are not privy to I will vote yes on all items including R/S. Either we trust Tony C and his team or you don't. If you don't it makes little sense to be invested at this point in the game.






Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News